News Medical: Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments
October 28, 2024
Mingjiang Xu, PhD, professor, Department of Molecular Medicine, was quoted in this article. Read More
October 28, 2024
Mingjiang Xu, PhD, professor, Department of Molecular Medicine, was quoted in this article. Read More
October 4, 2024
Simon Gayther, PhD, professor of medicine in the Division of Hematology and Oncology in the Joe R. and Teresa Lozano Long School of Medicine and founding director in the school’s Center for Inherited Oncogenesis at The University of Texas Health Science Center at San Antonio (UT Health San Antonio), received a $500,000 UT System […]
October 3, 2024
Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function. A study published October 2 in Nature is the first to explain the pathway […]